A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

Inclusion Criteria: * Subjects must have confirmed advanced solid tumor and have progressed, are refractory, or are intolerant to standard therapy appropriate for tumor type. Subjects should not have received more than 3 prior lines of therapy for recurrent or metastatic disease including both standards of care and investigational therapies. * Subjects must have at least 1 measurable lesion. * Consent to provide archived tumor specimens * Willingness to undergo pre-treatment and on-treatment biopsy. * Adequate organ function. * Use of highly effective contraception (females) or male condom plus spermicide (males). Exclusion Criteria: * Prior treatment with TNFRSF agonists. * Subjects who have received certain prior immunotherapy or had toxicities relating to prior immunotherapy may not be permitted to enroll. o Must not have required the use of additional immunosuppression other than corticosteroids for the management of an adverse event. * History of severe allergic reactions to any unknown allergens or any components of the study drug formulations. * Receipt of any conventional or investigational anticancer therapy within 28 days prior to the first dose of MEDI0562. * Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment. * Unresolved toxicities from prior anticancer therapy. * Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product.